Exchange: NASDAQ·Updated 05:06 AM EDT

HALO News

News
all
press releases
Halozyme to Report Third Quarter 2026 Financial and Operating Results
Halozyme to Report Third Quarter 2026 Financial and Operating Results Halozyme to Report Third Quarter 2026 Financial and Operating ResultsPR NewswireSAN DIEGO, Oct. 22, 2026 SAN DIEGO, Oct. 22, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will...
PR Newswire
Halozyme to Report Third Quarter 2026 Financial and Operating Results
Halozyme to Report Third Quarter 2026 Financial and Operating Results Halozyme to Report Third Quarter 2026 Financial and Operating ResultsPR NewswireSAN DIEGO, Oct. 22, 2026 SAN DIEGO, Oct. 22, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will...
PR Newswire
More News
The Zacks Analyst Blog Highlights Chord Energy, Halozyme, Sezzle, SanDisk and Teradyne
CHRD, HALO, SEZL, SNDK and TER boast strong margins and growth prospects, with earnings catalysts ahead as October 2026 results roll in.
Zacks
5 Strong Buy Growth Stocks With High Margins to Grab Before Earnings
Five Strong Buy stocks stand out ahead of earnings, combining high operating margins, revenue growth and exposure to AI, healthcare, energy and digital payments.
Zacks
ELV Beats Q3 Earnings Estimates on Carelon Strength, Raises 2026 Outlook
Elevance Health beats Q3 EPS estimate by 50% as Carelon grows despite declining medical membership, and lifts its 2026 underlying earnings baseline to $26.75.
Zacks
Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?
Here is how Climb Bio, Inc. (CLYM) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Zacks
The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics
Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics earn top Zacks rankings, backed by growth drivers ranging from streaming ads to drug demand.
Zacks
Zacks.com featured highlights include Halozyme Therapeutics, GigaCloud Technology, Lindblad Expeditions, Permian Resources and Chevron
Halozyme Therapeutics, GigaCloud Technology, Lindblad Expeditions, Permian Resources and Chevron stand out for strong share gains and rising earnings estimates under a relative price strength strategy.
Zacks
5 Stocks to Buy Using the Relative Price Strength Strategy
HALO, GCT, LIND, PR and CVX stand out as relative strength picks amid market volatility, backed by strong price performance and upbeat earnings estimates.
Zacks
Roche Gets FDA Approval for Enspryng in Thyroid Eye Disease
RHHBY wins FDA approval for Enspryng in thyroid eye disease, offering the first and only at-home subcutaneous treatment option for patients.
Zacks
KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome
Krystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.
Zacks

Advertisement|Remove ads.